Leidos Holdings, Inc. (LDOS) - Q2 2024 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 28, 2024. Leidos is a Fortune 500 innovation company providing technology solutions for national security and health sectors. Effective fiscal 2024, the company realigned its reporting structure into four segments: National Security and Digital, Health & Civil, Commercial & International, and Defense Systems. The company serves primarily U.S. government customers, including the Department of Defense and Intelligence Community.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenues | $4,132 million | $3,838 million | $8,107 million | $7,537 million |
| Operating Income | $475 million | $331 million | $890 million | $596 million |
| Operating Margin | 11.5% | 8.6% | 11.0% | 7.9% |
| Net Income (Attributable to Leidos) | $322 million | $207 million | $606 million | $369 million |
| Diluted EPS | $2.37 | $1.50 | $4.42 | $2.67 |
| Cash from Operations (YTD) | $437 million | $66 million | ||
| Cash & Equivalents (End of Period) | ||||
| Total Debt (Gross) | $4.7 billion | |||
| Backlog (Total) | $36.5 billion |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 7.7% year-over-year in Q2 and 7.6% year-over-year for the six-month period, driven by volume increases and program wins.
- Profitability Expansion: Operating income surged 43.5% in Q2 and 49.3% YTD. Operating margins improved significantly across most segments.
- Segment Performance:
- Health & Civil: Reported the strongest growth with operating income up 129.1% in Q2, driven by managed health services volumes and favorable business mix.
- Commercial & International: Recorded an operating loss of $11 million in Q2 (vs. $34 million profit prior year) due to $39 million in write-downs on UK programs related to cost increases and schedule delays.
- National Security and Digital: Steady growth with operating income up 6.4% in Q2.
- Cash Flow: Net cash provided by operating activities improved dramatically to $437 million YTD 2024 compared to $66 million YTD 2023, aided by higher earnings and lower tax payments.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management anticipates meeting liquidity needs through operating cash flow and existing credit facilities. The company expects to recognize approximately 63% of its $13.8 billion Remaining Performance Obligations (RPO) over the next 12 months.
- Unusual Items:
- Contract Write-downs: $39 million in unfavorable contract estimate changes in Q2, primarily within UK operations.
- Tax Rate: Effective tax rate increased to 23.9% in Q2 (from 23.4% prior year) due to reduced federal research tax credits.
- Risks and Contingencies:
- Government Investigations: Ongoing internal and external investigations regarding potential FCPA violations in international operations and an Antitrust Division subpoena regarding intelligence group procurements. Outcomes remain uncertain.
- Government Shutdown Risk: Reliance on U.S. government spending (86% of Q2 revenue) exposes the company to risks associated with potential federal government shutdowns if appropriations are not passed by September 30, 2024.
- Capital Allocation: The company repurchased $100 million of stock in Q2 and $250 million YTD. Dividends paid were $51 million in Q2.
Investor Verification Checklist
- UK Program Exposure: Verify the extent of the $39 million write-down in the Commercial & International segment and potential for future cost overruns in UK operations.
- Legal Proceedings: Monitor the status of the ongoing FCPA and Antitrust investigations for potential fines, penalties, or reputational damage.
- Backlog Quality: Assess the funded vs. unfunded backlog ratio ($8.0B funded vs. $28.5B unfunded) and the risk of unfunded requirements not being appropriated.
- Debt Covenants: Confirm continued compliance with the 3.75x debt-to-EBITDA covenant, especially given the increase in operating expenses in the Corporate segment.
- Health & Civil Sustainability: Evaluate whether the 129% jump in operating income for the Health & Civil segment is sustainable or driven by one-time write-ups.